Recent 8-K filings for NNVC
Highest-materiality recent filing
NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study
- Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
- After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.
-
NanoViricides raises ~$3.8M in registered direct offering of common stock and warrants
Gross proceeds of ~$3.8M from sale of 2,516,339 shares (or pre-funded warrants) and warrants to purchase 2,516,339 shares at $1.75.
-
Company entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC for at-the-market sales of common stock.
-
NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.
-
NanoViricides raises $2M in registered direct offering of shares and warrants
Offering of 1,333,334 shares (or pre-funded warrants) plus 1,333,334 warrants at $1.75, priced at $1.50 per share.
-
Anil Diwan re-elected as Class I Director with 9,757,652 votes in favor, 173,096 against.
-
NanoViricides raises $6M in registered direct offering and private placement with warrants
Offered 3,571,429 shares (or pre-funded equivalents) at $1.68/share for gross proceeds of ~$6M.
-
NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027
President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.
-
NanoViricides shareholders re-elect three directors and ratify auditor at 2024 annual meeting
Theodore Rokita re-elected with 2,060,147 votes for, 166,389 against.
-
NanoViricides extends President Diwan ($400k, 10k Series A shares) and CFO Vyas through June 2025
President Anil Diwan's employment extended to June 30, 2025 at $400,000 base salary.
-
NanoViricides names EF Hutton as sole sales agent for $50M ATM, removes B. Riley
EF Hutton LLC becomes sole agent under existing $50M at-the-market offering; B. Riley Securities removed.
-
NanoViricides defers TheraCour milestone payments until revenue; CEO extends Line of Credit
Amendment to TheraCour license defers future cash milestone payments (Milestones 4-7) until company achieves a Revenue Event; capped at 50% of Recognized Revenue.
-
At the January 13, 2024 annual meeting, shareholders re-elected Anil Diwan as Class I director with 5,590,467 votes for, 308,092 against, 488,175 abstentions, and 3,056,966 broker non-votes.
-
NanoViricides receives auditor consent for registration statement; no financial impact
EisnerAmper LLP consented to incorporation of its audit report from FY2023 10-K into S-3 registration statement.
-
NanoViricides issues $1.5M convertible note to TheraCour in lieu of milestone payment
Issued $1.5M convertible promissory note to TheraCour (related party) in lieu of $1.5M cash milestone payment under Licensing Agreement.
-
NanoViricides to redomicile from Nevada to Delaware effective May 30, 2023
Board and shareholders approved conversion to a Delaware corporation.
-
NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India
Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.
-
NanoViricides shareholders approve redomicile from Nevada to Delaware
On Feb 7, 2023, shareholders voted to reincorporate in Delaware from Nevada.
-
Directors Rokita (5.99M for), Jawadekar (5.95M for), Zucker (6.05M for) re-elected.
-
Employment extended through June 30, 2023; annual base salary of $400,000.
-
Anil Diwan re-elected as Class I director with 5,242,989 votes for, 137,944 withheld.
-
Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
-
NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash
Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event other_material